FDA Approves First Daily Weight Loss Pill You Can Take Anytime

Getting healthy just became easier for people who want to lose weight but dread needles.

The FDA approved Foundayo on Wednesday, a once-daily weight loss pill from Eli Lilly that can be taken any time of day without worrying about food or water. It's only the second GLP-1 pill approved for weight loss, joining Novo Nordisk's morning-only version that requires an empty stomach.

GLP-1 medications work by mimicking a natural hormone that tells your brain you're full, slows digestion, and helps regulate blood sugar. Until recently, these drugs only came as weekly injections like Wegovy and Zepbound, which have helped millions of people but left some patients hesitant about needles.

"One of the bigger barriers has been that some patients just don't want to take an injection," says Ken Custer, executive vice president of Eli Lilly. "For patients looking to get started with their weight management journey, maybe a pill is an easier place to start."

In clinical trials, people taking the highest dose of Foundayo for 18 months lost an average of 27 pounds, or about 12 percent of their body weight. Those taking a placebo lost just 2 pounds over the same period.

The pill form offers another major advantage beyond convenience. Pills are easier to manufacture than injections, which could help avoid the severe shortages that left patients scrambling for refills between 2022 and early 2025 when demand overwhelmed supply.

The Ripple Effect

This approval signals a turning point in how Americans can access weight loss treatment. Pills lower the barrier for people who avoided injections because needles felt too intimidating or made their condition seem more serious than they were ready to accept.

The FDA reviewed Foundayo in just 50 days through a new pilot program for drugs addressing national health priorities. Traditional approvals typically take six to 10 months.

People already taking injectable GLP-1s can switch to Foundayo while maintaining most of their progress. Studies showed those switching from Wegovy gained back just 2 pounds on average, while Zepbound users gained about 11 pounds.

The pill starts shipping April 6 through Eli Lilly's direct platform, with broader pharmacy availability following soon after.

More options mean more people can find a treatment that fits their lifestyle and comfort level.